Introducing JAK Inhibitors in Rheumatoid Arthritis

Introduction/Overview

The Human Canonical Model of JAK-STAT Signaling

The Biological Significance of Signaling Through Different JAK Combinations

Stratifying Non- or Inadequate- Treatment Response in RA

Tofacitinib JAK 1/3 Inhibitor: Clinical Trials in RA

Tofacitinib or ADA vs PBO in RA: Results From ORAL Standard

ACR 20 Responses Tofacitinib vs PBO: ORAL Solo

ACR 70 Responses Tofacitinib vs MTX: ORAL Start

ACR 20 Responses Tofacitinib vs PBO: ORAL Step

ACR 50 Responses Tofacitinib vs Tofacitinib + MTX and Adalimumab + MTX: ORAL Strategy

Baricitinib: Key Studies in RA Phase 3 Program and Their Characteristics

RA-BEAM Phase 3: ACR Outcomes at Weeks 12 and 24

RA-BEACON: Baricitinib in RA Patients With an Inadequate Response to TNF-ɑ Inhibitors

DARWIN 1 Phase 2: ACR Outcomes at Week 12 in MTX-IR: Filgotinib + MTX in Patients With Active RA

Other JAK Inhibitors in Development

JAK Inhibitors: Clinical Characteristics

Clinical Experience with JAK Inhibitors: Dr Fleischmann

ORAL Start: Patient-Reported Outcomes: Tofacitinib vs MTX

RA-BUILD Phase 3: PROs at Week 24 Baricitinib in csDMARD-IR and bDMARD-Naive Patients With Moderate to Severe RA

JAK Inhibitors: Safety Considerations

Summary and Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)